Stroke is a devastating condition with significant morbidity and mortality worldwide.
Antithrombotic therapy plays a crucial role in both primary and secondary prevention of …

This comprehensive review explores the incidence, pathophysiology, and management of
atrial fibrillation (AF) following percutaneous closure of patent foramen ovale (PFO) …

Background The optimal strategy for diagnosis and antithrombotic treatment of patients with
antiphospholipid syndrome (APS)–associated acute ischemic stroke (AIS), transient …

BACKGROUND: Following regulatory approval, medical devices may be used “off-label.”
Patent foramen ovale (PFO) closure is indicated to reduce recurrent stroke but has been …

Patent foramen ovale (PFO) is a common cardiac abnormality with a prevalence of 25% in
the general population. PFO has been associated with the paradoxical embolism causing …

Percutaneous closure of a patent foramen ovale (PFO), a common variation of interatrial
septum anatomy, is a commonly performed procedure in the catheterization laboratory to …

Patent foramen ovale (PFO) concerns nearly a quarter of the general population and
incidence may reach up to 50% in patients with cryptogenic stroke. Recent randomized …

Introduction: The aim of this study was to assess clinical outcomes and quality of life after
PFO closure in patients with previous stroke/TIA of undetermined cause and in patients with …

Introduction: Patent foramen ovale (PFO) closure prevents recurrent ischemic stroke in
selected patients with a cryptogenic stroke. Trial results tend to be generalized to daily …

Aging is the gradual decline in physical and physiological functioning leading to increased
susceptibility to stressors and chronic illnesses, including cardiovascular disease. With an …